Actelion signs key accord with GSK

The Swiss biotech company Actelion has signed a major deal with Britain's GlaxoSmithKline to develop and market the Basel firm's sleep medicine almorexant.

This content was published on July 14, 2008 - 10:28

In a statement on Monday, Actelion said the deal would be worth up to SFr3.3 billion ($3.23 billion).

The accord, under which GSK receives exclusive worldwide rights to co-develop and co-commercialise almorexant, ends months of speculation about whom Actelion might pick for cooperation on the drug.

almorexant is the first in a new class of medicines for insomnia, which had been considered an enticing prospect for many large drug companies.

Actelion said it would receive an upfront payment of SFr150 million and would be eligible for additional milestone payments of up to SFr415 million on the successful development and approval of amorexant in primary insomnia.

For Actelion, the successful development of almorexant is considered key to reducing its dependence on its main drug Tracleer.

Last week the Swiss stock exchange SWX announced that Actelion would be admitted to its Swiss Market Index of blue chip companies from September 22.

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.